glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

NBC TODAY on Foundayo (Oral GLP-1 Pill): Fact Check

Part of YouTube & Expert Fact Checks.

NBC TODAY on Foundayo (Oral GLP-1 Pill): Fact Check

NBC's TODAY show aired a segment on April 2, 2026 covering the FDA approval of Eli Lilly's new oral GLP-1 pill. The segment, reported by Anne Thompson, covers the drug's convenience advantages, weight loss data, pricing, and how it compares to the Wegovy pill. This review uses the video’s published description and automated transcript, checked against FDA information and trial reports. Automated transcripts can misidentify drug names; the clinical assessment below is updated to September 8, 2026.

The Drug Name in the Transcript

The automated transcript repeatedly renders the pill’s name as “Zepbound,” but TODAY’s published title and description correctly identify Foundayo. That discrepancy may be a transcription error. It does not justify saying the broadcaster repeatedly used the wrong name without checking the audio.
The drug distinction itself is clear: Foundayo is orforglipron, a daily oral GLP-1 agonist; Zepbound is tirzepatide, a weekly GLP-1/GIP injection. The FDA label identifies the approved pill.
See our Foundayo explainer and orforglipron vs Zepbound comparison.

No Empty Stomach Required

The segment highlights that the new pill can be taken at any time of day without regard to food — unlike the Wegovy pill, which requires fasting.

TODAY's ClaimPublished FactsVerdict
You can take it anytime a day without regard to foodFoundayo's FDA label confirms it can be taken at any time of day, with or without food, with no water restrictions. The Wegovy pill (oral semaglutide) requires an empty stomach, a sip of water only, and a 30-minute fast before eating.Accurate

This is one of Foundayo's genuine advantages. Because orforglipron is a non-peptide small molecule (not a peptide like semaglutide), it survives stomach acid and doesn't need the absorption-enhancing formulation that forces fasting requirements on peptide-based oral drugs.

For more on oral vs injectable GLP-1 drugs, see our oral vs injection comparison.

Weight Loss Data

The transcript reports roughly 12% average weight loss, or 27 pounds, at the highest studied dose. That closely matches Lilly’s ATTAIN-1 efficacy analysis: 12.4% at 72 weeks, assuming continued treatment.
The FDA label reports 11.1% versus 2.1% with placebo in adults without diabetes, using an analysis that includes treatment discontinuation. Those are different analyses, not contradictory results.

The broad statement that pills are less effective than injections needs qualification. This segment does not cite a direct comparison of Foundayo with the injectable products. Route alone does not establish a medicine’s effectiveness.

Pricing Claims

The segment’s $149 starter price and price up to $349 reflect the launch pricing discussion. They are not a promise that every viewer can obtain every dose at that price.

As checked on September 8, Lilly’s terms retain the $149 starter price. Temporary self-pay offers reduce 2.5 mg to $149 and 5.5 mg to $199 through December 31, 2026. The 14.5 and 17.2 mg doses have a $299 offer requiring subsequent refill purchases within 45 days; their regular price is $349. That is an offer condition, rather than a separate late-payment penalty.
Commercial-insurance savings have eligibility rules and limits. See the current pricing section for the distinction between self-pay offers, insurance savings and Medicare Bridge eligibility.

Market Size Projections

The transcript gives a market forecast of about $73 billion in 2026 and $250 billion by 2034. Fortune Business Insights publishes a forecast in that range.

This is an analyst projection, not an observed future outcome or evidence of clinical benefit. The transcript does not name the forecasting source, so matching numbers alone does not establish which report TODAY used.

Side Effects

The transcript identifies nausea and gastrointestinal problems, which are recognized adverse reactions. Its suggestion of equal severity across pills and injections is too broad.

The Foundayo label pools two weight-management trials. At the highest equivalent dose, nausea occurred in 35%, diarrhea in 25%, vomiting in 24% and constipation in 24%. The label warns that adverse-reaction rates from different drug trials cannot be directly compared.
These figures neither prove that Foundayo is harsher than injections nor establish equal severity. The medicine also has important contraindications and warnings, including a boxed thyroid C-cell tumor warning. The Foundayo explainer summarizes the label’s practical implications.

Overall Verdict

The segment accurately describes a newly approved oral GLP-1 medicine that does not require fasting, and its weight-loss headline matches an ATTAIN-1 efficacy analysis. Pricing needs eligibility and date context. Comparisons with injections require more care than the segment’s broad wording suggests.

The apparent drug-name error remains a transcript discrepancy, because the video’s published title and description correctly say Foundayo. It should not be presented as a confirmed on-air mistake.

Frequently Asked Questions

Frequently Asked Questions

What drug did the TODAY show say was approved?

The published title and description identify Foundayo. The automated transcript renders the name as Zepbound, but that discrepancy is not enough to establish an on-air error. Foundayo is the oral medicine FDA approved on April 1, 2026.

Is Foundayo the same as Zepbound?

No. Foundayo (orforglipron) is a daily oral pill that targets only the GLP-1 receptor. Zepbound (tirzepatide) is a weekly injection that targets both GLP-1 and GIP receptors. Both are made by Eli Lilly but they are different drugs with different active ingredients and different levels of weight loss efficacy.

How much weight can you lose on the new GLP-1 pill?

The ATTAIN-1 efficacy analysis reported 12.4% average loss at 72 weeks. The FDA label’s analysis including treatment discontinuation reports 11.1% at the highest equivalent dose, versus 2.1% with placebo, in adults without diabetes.

How much does Foundayo cost per month?

The starter self-pay price is $149 per 30-day supply. Higher-dose prices depend on current offers and refill conditions; 14.5 and 17.2 mg have a $299 conditional offer and $349 regular price. Insurance savings have separate eligibility requirements.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo (orforglipron) received FDA approval for adult weight management on April 1, 2026.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all fact checks topics →